NCT05079360 2023-03-24
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Veru Inc.
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT03238703 2018-12-27
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Fred Hutchinson Cancer Center
Phase 4 Withdrawn
NCT00615524 2018-01-12
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT01240928 2013-08-20
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01240941 2013-08-20
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT00080613 2013-07-10
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01658176 2012-10-29
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
Pfizer
Phase 2 Withdrawn
NCT01005641 2012-07-13
ELBA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT00057993 2012-06-11
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Northwestern University
Phase 2 Withdrawn
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn